X4 Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Growth Equity Opportunities 18 VGE, LLC and affiliated NEA entities increased their beneficial ownership in X4 Pharmaceuticals, Inc. to 6.2% following participation in a recent underwritten offering.
NASDAQ
Coastlands Capital and related entities report a 9.99% beneficial ownership in X4 Pharmaceuticals following a recent private placement.
NASDAQ
Growth Equity Opportunities 18 VGE, an affiliate of New Enterprise Associates, increased its beneficial ownership in X4 Pharmaceuticals, Inc. to 9.99% through a recent private placement.
NASDAQ
Bain Capital Life Sciences entities have significantly increased their beneficial ownership in X4 Pharmaceuticals to 9.99% following a new financing round and concurrent executive leadership changes.